Drilldown: Medicines
Medicines > onset 
:
BP and symptomatic LUTS improvement within 1-2 weeks or
Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months or
Postprandial glucose effect within days; HbA1c by 12 weeks
:
BP and symptomatic LUTS improvement within 1-2 weeks or
Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months or
Postprandial glucose effect within days; HbA1c by 12 weeks Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (3) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Heart_failure_medications|Heart failure medication]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2) ·
[[:Category:SGLT2_inhibitors|SGLT2 inhibitor]] (1)
mechanism:
None (3) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
preparations:
fda max:
routes:
onset: (Click arrow to add another value)
duration:
halflife:
bioavailability:
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) ·
High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) ·
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1) ·
~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
pregnancy:
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
Showing below up to 5 results in range #1 to #5.